SOD1 and amyotrophic lateral sclerosis: Clinical studies, including a randomized, placebo-controlled trial published in the New England Journal of Medicine by Miller et al. [115], have demonstrated that repeated intrathecal injections of tofersen result in sustained reductions in SOD1 protein levels and a slower decline in functional status among patients with SOD1-ALS.